** Hong Kong-listed Lepu Biopharma 2157.HK jumps 14.2% to HK$2.73; set for biggest one-day pct gain since Dec. 17, 2024
** Stock hits highest since Dec. 27, 2024; on track for fifth consecutive session of gains
** Co grants exclusive global rights to ArriVent BioPharma AVBP.O to develop and commercialize Lepu's novel antibody drug conjugate candidate MRG007, which is used to treat gastrointestinal cancers, outside of Greater China
** Lepu will get one-time upfront and near-term milestone payments of $47 mln
** Eligible to get up to $1.16 bln in development, regulatory and sales milestones and tiered royalties in high single-digit to low-teen percentages on net sales in Licensed Region
** AVBP rose 3.7% on Tuesday
** Lepu fell ~38% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。